Patent ID: 8211925

Claim:
A pharmaceutical composition comprising a compound of Formula I or a salt thereof wherein B is a direct bond or —O—; R 1 is C 1-6 -alkyl, C 1-4 -alkoxy-C 1-4 -alkyl, C 3-7 -cycloalkyl, C 3-7 -cycloalkyl-C 1-4 -alkyl or C 3-7 -cycloalkyl-oxy-C 1-4 -alkyl, each of which is optionally substituted with one or more substituents independently selected from R 3 ; R 3 is independently selected from hydroxy, —CF 3 , methyl and F; with the proviso that Y—X— cannot be CH 3 —O—, C 2 H 5 —O—, or CH 3 C(O)—O—; X is a linker independently selected from —O—Z— and —O—Z—O—Z—, wherein the O is attached to the phenyl ring; each Z is independently selected from a direct bond, C 2-6 alkenylene, and —(CH 2 ) p —C(R 10 ) 2 —(CH 2 ) q —; Y is selected from aryl-Z 1 —, a 5-10 membered heterocyclyl-Z 1 —, wherein the heterocyclyl consists of carbon atoms and 1-4 heteroatoms selected from O, N, and S(O) t , C 3-7 cycloalkyl-Z 1 —, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —(CH 2 ) 1-4 CH 2 F, —(CH 2 ) 1-4 CHF 2 , —(CH 2 ) 1-4 CF 3 , —CH(OH)CH 2 F, —CH(OH)CHF 2 , and —CH(OH)CF 3 , wherein each Y is optionally substituted with 1-3 substituents independently selected from R 4 ; Z 1 is independently selected from a direct bond, C 2-6 -alkenylene, and) —(CH 2 ) p —C(R 10 ) 2 —(CH 2 ) q —; p is independently selected from 0, 1, 2, and 3; q is independently selected from 0, 1, 2, and 3; p+q is selected from 0, 1, 2, and 3; R 4 is independently selected from R 5 —X 1 —, Cl, F, Br, I, CH 2 F, CHF 2 , CF 3 , cyano, amino, C 1-6 alkyl, —OC 1-6 -alkyl, carboxy, —C(O)OR 7 , hydroxy, and phenyl optionally substituted by C 1-6 alkyl or —C(O)OR 7 , wherein X 1 is defined as X above; R 5 is selected from H; C 1-6 alkyl; CH 2 F; CHF 2 ; CF 3 ; phenyl; naphthyl; a 5-10 membered heterocyclyl consisting of carbon atoms and 1-4 heteroatoms selected from O, N, and S(O) t ; and a C 3-7 cycloalkyl, and each R 5 is optionally substituted by one or more substituents independently selected from R 6 ; R 6 is independently selected from Cl, F, Br, I, C 1-6 alkyl, —OC 1-6 alkyl, CH 2 F, CHF 2 , CF 3 , cyano, hydroxy, amino, C(O)OH, and —C(O)OC 1-6 alkyl; R 7 is independently selected from C 1-8 -alkyl and C 3-8 -cycloalkyl; A is a 5-10 membered heterocyclyl, wherein the heterocyclyl consists of carbon atoms and 1-4 heteroatoms selected from O, N, and S(O) t , substituted with R 8 ; R 8 is —(CH 2 ) 1-2 —COOH, optionally substituted with one or more substituents independently selected from R 9 ; R 9 is independently selected from C 1-4 -alkyl, hydroxy and F; R 10 is independently selected from H, Cl, F, Br, I, C 1-6 -alkyl, and —C 2-4 -alkyl-O—C 1-4 alkyl; t is independently selected from 0, 1, and 2; and a pharmaceutically acceptable diluent or carrier.